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Abstract. Leptospirosis is a global zoonotic disease caused by pathogenic bacteria of the Leptospira genus, which
are fastidious, slow-growing organisms. Antimicrobial susceptibility data are limited; traditionally, the organisms have not
been culturable on solid media. The recent development of Leptospira Vanaporn Wuthiekanun (LVW) agar, which facil-
itates rapid growth of Leptospira spp., provides the opportunity for antimicrobial susceptibility testing. Eighty-three
Leptospira spp. clinical isolates originating from patients in Laos between 2006 and 2016 were tested against six
antimicrobials (azithromycin, ceftriaxone, ciproﬂoxacin, doxycycline, gentamicin, and penicillin G) using disk diffusion on
LVW agar. Quality control was undertaken using American Type Culture Collection (ATCC) reference strains with known
susceptibilities on both standard media and LVW agar. All Leptospira spp. isolates produced large zones of inhibition
around each of the six antimicrobials. All zones were greater than 25 mm: gentamicin produced the smallest zones
(median 35 mm; interquartile range 30 mm–37 mm) and azithromycin produced the largest zones (median 85 mm;
interquartile range 85mm–85mm). Zones produced by non-leptospiral ATCC reference strains on LVW agar were within
2 mm of accepted strain-speciﬁc quality control range on standard media. Antimicrobial activity on LVW agar appears to
be similar to that on standard media. As there are no published susceptibility guidelines for the Leptospira genus, zone
interpretation was subjective. Leptospira Vanaporn Wuthiekanun agar enabled antimicrobial susceptibility testing of
multiple Leptospira isolates on solid media; the large zone sizes observed suggest that resistance has not emerged to
these six antimicrobials in Lao Leptospira spp.
INTRODUCTION
Leptospirosis is a widespread zoonosis caused by spiro-
chete bacteria of the genus Leptospira. Although present
worldwide, the highest disease burden is in tropical and
subtropical areas, including Southeast Asian countries such
as the Lao People’s Democratic Republic (Laos), where it is
commonly under-recognized.1 The infection is spread to hu-
mans through environmental contamination by the urine of
infected animals and causes a spectrum of clinical presenta-
tions ranging from mild febrile illness to severe disease that
can result in organ failure and death.2 First-line therapy for
severe leptospirosis is intravenous penicillin with oral doxy-
cycline or azithromycin indicated in less-severe disease.3
Because of limited diagnostic capability and nonspeciﬁc
clinical presentation, leptospirosis patients are commonly
treated empirically for undifferentiated fever usually with beta-
lactams, doxycycline, gentamicin, or ciproﬂoxacin.4–8
Antimicrobial susceptibility testing is used to determine the
in vitro activity of agents against microorganisms and several
different methods are available.9 Agar-based culturemethods
are a mainstay in susceptibility testing for their ability to fa-
cilitategrowthofmanypathogenswithin 24hours.10However,
susceptibility testing of Leptospira spp. has been limited as
leptospires are fastidious, slow-growing organisms unable to
grow on standard laboratory media.10,11 There has thus been
no robust method of culturing leptospires on solid media and
no standardmethod for in vitro testing of antimicrobial agents
against Leptospira spp.10–12 Culture using special liquid or
semiliquid media can be performed but is labor intensive, re-
quiring expertise and may take weeks to months to achieve
growth.10,13 Both macro- and micro-dilution methods have
been used to test the susceptibility of isolates from humans
and animals, but they are time consuming and difﬁcult to
control.10,11Both clinical evidenceand in vitro studies suggest
that leptospires are susceptible to beta-lactams, macrolides,
tetracyclines, and ﬂuoroquinolones, but the lack of large-scale
studies means there is little information about the prevalence
of antimicrobial resistance within the genus.14–23
The ﬁrst solid medium for Leptospira spp. named Lep-
tospira Vanaporn Wuthiekanun (LVW) agar, which facilitates
rapid growth, was developed in 2013.10 The culture of Lep-
tospira spp. using LVW agar entails initial incubation at 30C
in 5%CO2 for 2 days followed by incubation in ambient air at
30C for 5 days, with growth visible by this time.10 A small
pilot study demonstrated the use of LVW agar for antimi-
crobial susceptibility testing in disk diffusion assays.24
The aim of our study was to expand on this initial study and
use disk diffusion assays on LVW agar to assess the antimi-
crobial susceptibility of 83 LaohumanLeptospira spp. isolates
to six antimicrobials (azithromycin, ceftriaxone, ciproﬂoxacin,
doxycycline, gentamicin, and penicillin G), which are com-
monly used to empirically treat fever in Laos.25–27 To validate
the use of disc diffusion susceptibility testing for leptospires
on LVW agar, we compared the activity of the antimicrobials
against control strains from the American Type Culture Col-
lection (ATCC) on LVW agar to that on Mueller–Hinton agar.
MATERIALS AND METHODS
Clinical isolates. Eighty-three Leptospira spp. isolates
were tested from a collection of clinical isolates originating in
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Laos between 2006 and 2016. The isolates were isolated from
blood clots of Leptospira-positive patients at four Lao hospi-
tals (Mahosot Hospital and Friendship Hospital in Vientiane,
Luang Namtha Provincial Hospital, and Salavan Provincial
Hospital) during studies of the etiology of fever.8 The isolates
were maintained in Ellinghausen–McCullough–Johnson–
Harris (EMJH) broth at room temperature from the day of
isolation and subcultured approximately every 6 months be-
fore use in this study. To maximize viability at the time of
susceptibility testing, the isolates were subcultured before
inoculation on LVW agar.
Preparation of LVW agar and EMJH broth. Leptospira
Vanaporn Wuthiekanun agar was prepared as described by
Wuthiekanun et al.10 Brieﬂy, for 1 L of LVW agar, 2.3 g of
LeptospiraMedium Base EMJH (BD Difco, Sparks, MD), 10 g
of Noble Agar (BD Difco), and 1 mL of 1% sodium pyruvate
(Merck, Billerica, MA) solution were added to 800 mL of dis-
tilled water. After autoclaving, 100 mL of Leptospira Enrich-
ment EMJH (BD Difco) and 100 mL of normal rabbit serum
(Gibco) were aseptically added. The agar was poured, dis-
pensing 25mL into a 90-mmdiameter Petri plate for a depth of
4 mm. Each batch of LVW agar was tested with an in-house
clinical isolate of Leptospira spp. (UI130) to conﬁrm that
it supported growth of Leptospira spp. Ellinghausen–
McCullough–Johnson–Harris broth was prepared following
LVW agar preparation, with ﬁnal concentration of agar at
0.1% and rabbit serum at 3%.
Inoculation of ATCC reference strains on LVW agar and
standardmedia. The following strains were used to compare
zone diameters produced on LVW agar with those on Clinical
and Laboratory Standards Institute (CLSI) standard media:
Escherichia coli ATCC 25922, Staphylococcus aureus ATCC
25923, Pseudomonas aeruginosa ATCC 27853, and Strep-
tococcus pneumoniae ATCC 49619. All other conditions of
disk diffusion were as deﬁned by CLSI, except that Mueller–
Hintonwith 5%goat bloodwas used forS. pneumoniaeATCC
49619 instead of sheep bloodwhich is not available in Laos.28
The zones produced on standard media and LVW agar were
compared with the strain-speciﬁc quality control zone ranges
on standard media.28 Note that only antimicrobials with pub-
lished ranges for a speciﬁc strain were used.
Estimation of culture concentration using microscopy.
Growth was monitored by dark-ﬁeld microscopy (Olympus
BX51) and assessed using a 0–4-point growth scale de-
veloped by Mahidol Oxford Tropical Medicine Research Unit
(Bangkok, Thailand) to estimate Leptospira spp. viability and
concentration in EMJH broth. Peak viability was denoted as
4+ growth and was visualized by high motility and dense
coverage of leptospires across the ﬁeld when viewing a 5-μL
drop of culture with the ×10 objective. This indicated a lep-
tospire concentration of approximately 1 × 108 CFU/mL, the
desired concentration for inoculation of LVW agar. The iso-
lates were inoculated within 24 hours of reaching 4+ growth,
after which time the culture ceased to be considered fresh as
indicated by clumping of the bacteria.
Inoculation, incubation, and application of antimicrobial
disks. Isolates that had attained 4+ growth were inoculated
onto LVWagar by dispensing 300 μL of culture onto the center
of a single plate and spreading the bacteria with a cotton swab
using a rotary plater (Leetech). Seven plates were inoculated
with each isolate—one for each of the six antimicrobials (only
one disk was applied to each plate as the zones were
anticipated to be very large) and one growth control plate with
no disk.
Once dry, the inoculated plates were inverted, placed in a
candle jar (estimated 2–3%CO2),
29 and incubated at 30C for
48 hours.
Six antimicrobials (Table 1) were tested by disk diffusion as
previously described.24 On day 3 of incubation, each disk
(Oxoid™, Basingstoke, United Kingdom) was aseptically ap-
plied to the center of a single plate, apart from the control. The
plates were inverted and incubated at 30C in ambient air for
5–12 days, depending on individual growth rates.
Measuring growth and repeat inoculation of four
isolates.Growthwasmonitored fromday 6 of incubation, and
ﬁnal measurements were taken between days 8 and 13,
depending on individual growth rates. The zones of inhibition
were measured from the innermost point of growth as seen
with the naked eye. Any visible contamination or difﬁculty
measuring zones was noted. Four isolates underwent repeat
testing to assess reproducibility. The isolates were re-
subcultured before the repeat inoculation.
RESULTS
Comparison of zone diameters on LVW agar and stan-
dard media. All zones produced by E. coli ATCC 25922,
S. pneumoniae ATCC 49619, S. aureus ATCC 25923, and
P. aeruginosa ATCC 27853 on CLSI standard media were
within the strain-speciﬁc quality control ranges published in
CLSI guidelines (Table 2).26 The zones produced by these four
reference strains on LVW agar were also within the strain-
speciﬁc ranges for standard media except in the following
cases.Escherichia coliproduced zones 2mmsmaller than the
minimum range value for ceftriaxone and doxycycline.
Streptococcus pneumoniae produced a zone 1 mm larger
than the maximum range value for azithromycin and 1 mm
smaller than theminimum range value for doxycycline. Finally,
S. aureus produced a zone 2 mm larger than the maximum
range value for azithromycin.
Growth on LVWagar. The Leptospira spp. isolates grew at
variable rates on LVW agar with growth appearing between
day 8 and 13 of incubation. Zones of inhibition were often not
distinct until 1 or 2 days after growth initially appeared. Ap-
proximately half of the inoculated plates could be measured
on day 8.
Once visible, there was variability in the appearance of the
growth. Although all growth was subsurface and had a white
cloud-like appearance (Figure 1), there was a range in the
distinctness and apparent density of growth. In particular, 18
isolates had fainter growth across all plates, although zones of
inhibition were still distinguishable. All isolates had visible
growth on the growth control plate except in three cases
TABLE 1
Six antimicrobials used for disk diffusion susceptibility testing
Antimicrobial Disk content Catalog number (Oxoid)
Azithromycin 15 μg CT0906B
Ceftriaxone 30 μg CT0417B
Ciproﬂoxacin 5 μg CT0425B
Doxycycline 30 μg CT0018B
Gentamicin 10 μg CT0024B
Penicillin G 10 units CT0043B
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where there was either widespread surface plate contamina-
tion (two isolates) or insufﬁcient culture volume to inoculate
the control (one isolate).
Large zones of inhibition produced by Leptospira spp.
isolates. All Leptospira spp. isolates produced zones more
than 25 mm in diameter for each of the six antimicrobials
(Figure 2). Plates on which no growth was visible (but with
growth on the corresponding control) were assumed to have a
zone of 85 mm or larger, the diameter of the plate base.
Gentamicin produced the smallest zones, with a median zone
diameter of 35 mm (interquartile range 30 mm–37 mm) and a
range between 25 and 85 mm. Azithromycin produced the
largest zones with a median zone diameter of 85 mm
(interquartile range 85 mm–85 mm) and a range between 37
and 85 mm (note that the interquartile range, median, and
maximum zone of azithromycin lie on the same value). Cef-
triaxone, ciproﬂoxacin, doxycycline, and penicillin G pro-
duced intermediate zone medians at 69, 70, 56, and 70 mm,
respectively. No plate had growth within 25 mm of any disk.
Zone interpretation. Eight percent of zones were noted as
difﬁcult tomeasure (Figure 3). These included zones that were
not perfectly circular (for which a mean of two measurements
was calculated) and zones which did not extend to a full circle
(for which the radius was measured and doubled if a diameter
could not be read). Also included were zones which were
difﬁcult to distinguish from growth resulting from excess ﬂuid
build-up at the edge of the plate during inoculation. This oc-
curred most often with very large zones almost reaching the
plate edge. In addition, azithromycin produced zones with
very faint outlines, even if the rest of the plates for a given
isolate had distinct growth and zones.
Repeat testing of four isolates. Four isolates were tested
multiple times to assess reproducibility of the method. Isolate
LNT3110 was tested twice, and zones for each antimicrobial
between replicates were within 3 mm of each other (Table 3).
The zones produced by LNT2714 had differences of more
than 5 mm between replicates for each antimicrobial. The
zones produced by UI27257 had differences of more than
8 mm between replicates for each antimicrobial with a large
difference of 34 mm between zones for ceftriaxone. Isolate
FS3849 was tested three times and ranges between the
maximumandminimumzone diameters produced in the three
tests were 15, 18, 19, 7, 8, and 21 mm for azithromycin,
ceftriaxone, ciproﬂoxacin, doxycycline, gentamicin, and peni-
cillin G, respectively.
DISCUSSION
This study, testing 83 clinical isolates of Leptospira spp.
collected over a 10-year period against six antimicrobials, is
the largest study to date we are aware of to use disk diffusion
assays on LVW agar for susceptibility testing of Leptospira
spp.10,12,24,30 The data suggest that all isolates were sus-
ceptible to the six antimicrobials and that the agents were
highly active in LVW agar. There is, thus, no evidence that
leptospires in Laos have developed resistance to standard
antimicrobial therapy.4–8
All Leptospira spp. isolates in this study produced large
zones of inhibition, indicating high sensitivity to the six anti-
microbials. As there are no published susceptibility guidelines
for Leptospira spp., interpretation of the zone sizes is sub-
jective and the isolates cannot be deﬁnitively classed as
susceptible, intermediate, or resistant.10,11,31 However, the
large zone sizes suggest a high level of antimicrobial activity in
comparison with the zone sizes that would be expected with
other bacteria according to CLSI guidelines.28 It should be
noted, however, that the longer incubation period needed to
allow growth of Leptospira spp. is likely to have resulted in
larger zone diameters than would be observed for faster
growing organisms. The similar zone sizes producedbyATCC
reference strains on both standard and LVW agar, where no
zone was more than 2 mm outside the respective CLSI range,
suggest that the antimicrobials have similar activity in both
media.
There was a range of zone sizes produced by Leptospira
spp. isolates for each antimicrobial. Although these ranges
may represent slight differences between the susceptibilities
of individual isolates to the antimicrobials, the zones were still
very large, suggesting that all isolates were susceptible.
TABLE 2
Zones of inhibition (mm) of ATCC reference strains on CLSI standard media and LVW agar28
Antimicrobial
Escherichia coli
ATCC 25922
Staphylococcus aureus
ATCC 25923
Pseudomonas aeruginosa
ATCC 27853
Streptococcus pneumoniae
ATCC 49619
CLSI range Mueller–Hinton LVW CLSI range Mueller–Hinton LVW CLSI range Mueller–Hinton LVW CLSI range Mueller–Hinton with 5% goat blood LVW
Azithromycin – – – 21–26 26 28 – – – 19–25 25 26
Ceftriaxone 29–35 34 27 – – – – – – 30–35 33 31
Ciproﬂoxacin – – – – – – 25–33 30 30 – – –
Doxycycline 18–24 24 16 – – – – – – 25–34 31 24
Gentamicin 19–27 23 24 19–27 26 25 17–23 21 23 – – –
Penicillin G – – – 26–37 37 26 – – – 24–30 26 24
ATCC=American TypeCultureCollection; CLSI =Clinical and Laboratory Standards Institute; LVW= LeptospiraVanapornWuthiekanun.Note that only antimicrobialswith published ranges for a
speciﬁc strain were used. Clinical and Laboratory Standards Institute quality control ranges on standard media are also given.
FIGURE 1. Growth of Leptospira spp. isolates on Leptospira Vana-
pornWuthiekanun agar. (A) Growth control of isolate UI36718 with no
antimicrobial disk. (B) Zone of inhibition (55 mm) of isolate UI22068
around penicillin G. This ﬁgure appears in color at www.ajtmh.org.
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Gentamicin, which generally diffuses poorly through media
and, thus, tends to produce smaller zones than some other
agents, produced the smallest zones.28 Azithromycin pro-
duced the largest zones, withmany isolates demonstrating no
visible growth, thus indicating a zone greater than the di-
ameter of the plate. The four other antimicrobials used in this
study had zone ranges intermediate between gentamicin and
azithromycin, but all large relative to CLSI susceptibility
breakpoints for other organisms.28 The four isolates were
tested multiple times to assess reproducibility. The results
suggest that although there is considerable inherent variability
in themethod, it doesnot detract from thekeyobservation that
no obvious resistance was detected among the isolates.
Several elements of the methodology contributed to the
qualitative nature of the study. First, zone interpretation was
subjective with growth often difﬁcult to visualize on the agar.
Cultures of Leptospira spp. are different in appearance from
many other bacteria on solid media as growth is subsurface
and has a hazy, cloud-like appearance; therefore,many plates
had zones that were difﬁcult to measure.
Second, determination of the inoculum concentration be-
fore inoculation was also subjective. Dark-ﬁeld microscopy
wasused to assess isolate growthwith “4+growth”presumed
to indicate a concentration of 1 × 108 CFU/mL. This visual
assessment is dependent on drop thickness on the micro-
scope slide and made more difﬁcult by varying leptospire
lengths in different Leptospira isolates. Irregularity in inoculum
concentration can affect zone size, for example, where higher
concentrations can result in comparatively smaller zone sizes
across all antimicrobials as exhibited by isolates FS3849
and SV588.
The Leptospira spp. isolates exhibited individual growth
rates as demonstrated by variation in both the time to reach 4+
growth after subculturing and time for visible growth to appear
on LVW agar. Although the median time to reach 4+ growth
was 5 days, 21 isolates were fast growing taking 3 days and
two isolates were slow growing taking 12 days to reach 4+
growth. In addition, 18 isolates exhibited discernibly fainter
growthonLVWagar, evenwhenmeasuring zonesonday13of
incubation. Given the possibility of inoculum concentration
variability, it cannot be determined if the faint growth observed
was due to low inoculum concentration or slow isolate growth
rate.
FIGURE 2. Median zonesof inhibition (mm) producedby Leptospira spp. isolates to six antimicrobials on LeptospiraVanapornWuthiekanun agar.
The box indicates interquartile rangewithmedian and bars indicateminimumandmaximum values. The interquartile range, median, andmaximum
zone of azithromycin lie on the same value.
FIGURE 3. Difﬁcult tomeasure zones of inhibition of Leptospira spp.
isolates on Leptospira Vanaporn Wuthiekanun agar. (A) Zone that is
not perfectly round. (B) Zone that does not extend to a full circle. (C)
Multiple zones. This ﬁgure appears in color at www.ajtmh.org.
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Contamination, the source of which was unclear, was a
problem throughout the study although zones could still
usually be read. The long duration of incubation meant that
contamination was more problematic than in the testing of
more rapidly growing pathogens. Most isolates could only be
tested once because of resource constraints.
Our data highlight that although antimicrobial susceptibility
testing of Leptospira spp. is challenging and a suitable con-
sensus methodology is required,12 the use of disk diffusion
assays on LVW agar suggest that clinical Leptospira spp.
isolates in Laos remain susceptible to standard antimicrobial
therapy. These results are consistent with the limited body
ofevidenceofLeptospiraspp.susceptibilityusingbrothmacro-and
micro-dilution,which also suggest a lackof leptospire resistance to
commonly prescribed antimicrobials.6,7,12,14–17,19–23,32,33 This may
be related to the fact that the normal reservoirs of leptospires
are environmental sources and wildlife, which generally have
minimal selective pressure from antimicrobials, unless they
are associated with sewage outlets or watercourses where
antimicrobial residues may be found.33 There are thus no
implications from this study that empirical or deﬁnitive
treatment strategies for leptospirosis in Laos need to be
modiﬁed.
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Supplementary materials 
S1 Table. Zones of inhibition (mm) produced by Leptospira spp. isolates for 6 antimicrobials on LVW agar. Also included is the time to reach 4+ 
growth following subculturing and observation of faint growth. Time to reach 4+ growth is also given for 6 plates of different isolates where the 
isolate was re-subcultured and tested at a separate time. Basic statistical computations for each antimicrobial such as median and mode are 
located at the bottom of the table. 
Isolates codes: UI = patient admitted at Mahosot Hospital, Vientiane; LNT = admitted at Luang Nam Tha Hospital; SV = admitted at Salavan 
Hospital; FS = admitted at Friendship Hospital, Vientiane. 
+ Growth on the control without an antimicrobial disk; 
* Surface plate contamination; 
† Difficult to measure zones. 
Isolate  
number 
Isolate  
code 
Growth 
control Azithromycin Ceftriaxone Ciprofloxacin Doxycycline Gentamicin Penicillin G
Time to reach 
4+ growth 
(days) 
Additional 
observations 
 1  UI8368 + 85 85 85 40 35 58 6 Faint growth 
 2  UI8414 + 85 59 70  85* 33 85 6  
 3  UI8434 + 85 54 70* 51 30 65 5 Faint growth 
 4  UI8440 + 85 68 70 68 32 72 5  
 5  UI8561  +* 85 40 85 85 85 75 6  
 6  UI8596 + 85  75* 70 60 48 69 6 Faint growth 
 7  UI8704 + 85 60 70 55 36 60 6  
 8  UI12344 + 85 64   57*† 34  30*  65* 6  
 9  UI12342 + 85  85* 85 70 47 72 5 Faint growth 
Isolate  
number 
Isolate  
code 
Growth 
control Azithromycin Ceftriaxone Ciprofloxacin Doxycycline Gentamicin Penicillin G
Time to reach 
4+ growth 
(days) 
Additional 
observations 
 10  UI12621 + 77  60*   65*† 59 26 63 12  
 11  UI12764  + 85  70*  85*  70* 43*  80* 8 Faint growth 
 12  UI12758  +* 80 52 73 48 28 65 8  
 13  UI12769 + 85 80 85 70 35 71 3 Faint growth 
 14  UI12830  +* 85 75 68 65 35 70 6  
 15  UI13005 + 75 52 68 53 27   73† 12  
 16  UI13016 + 85 60 65 50 35 68 3  
 17  UI12823 Widespread Contamination  85* 65  85* 50 40 80 6 Faint growth 
 18  UI13087  +* 85  65†  45†  57* 30  60* 6  
 19  UI13098 + 75  70† 55 45 43 70 5 Faint growth 
 20  UI13372 Widespread Contamination 75 64 65 60 34 69 8  
 21  UI14346 +  85*  70* n/a n/a 33 70 5  
 22  UI14469 + 85  75* 60 60 34 80 4 Faint growth 
 23  UI14535  +* 85 60 60 50 32 70 4 Faint growth 
 24  UI14631 + 85 76 70 70 35 80 8  
 25  UI14721 +  85*  49* 64 45 31 70 9  
 26  UI14851 + 85 80 70 74 37 76 8 Faint growth 
 27  UI15117 + 60 54  60* 50 40 70 4  
 28  UI15191  +* 85 60 65 49 30 70 4  
 29  UI15218 +  85* 70 Widespread Contamination 59 39 66 8  
 30  LNT1154 + 85    64*†  67*† 60 31  59* 9  
 31  SV387 +   37† 45  40*  45† 25 54 6  
 32  UI15308 + 80 65 70 64 33 68 4  
 33  UI15357 + 85 70 70 55 35 70 5  
 34  UI17545  +* 85 70 79 51 39 64 4  
Isolate  
number 
Isolate  
code 
Growth 
control Azithromycin Ceftriaxone Ciprofloxacin Doxycycline Gentamicin Penicillin G
Time to reach 
4+ growth 
(days) 
Additional 
observations 
 35  UI17322 +  85* 74 85 67 32 73 3  
 36  LNT1600  +* 85 59 65 45  32* 70 5  
 37  LNT1612 +  85* 65 75  (4 days) 60 
35  
(4 days) 85 5  
 38  LNT1671 n/a 85  75† 85  63† 36 85 4 Faint growth 
 39  UI18681 +  85*   70*†  69† 55 28*    74*† 9  
 40  UI19245 + 85 70 85  85* 35 85 5 Faint growth 
 41  UI19893 +  85* 70 70  70† 30 74 3  
 42  UI20184 + 68 63 69 59 35  68* 7  
 43  LNT2340 + 85  71† 65 64 38   73† 6  
 44  UI20403 + 85 72 85 60 35 72 3  
 45  UI20802 + 85  85* 85 70 35 85 3 Faint growth 
 46  SV865  +* 85 60  (4 days) 
70 
(4 days) 47  35* 67 3  
 47  UI11076  +*  85*    85*† 85*  69* 39  85* 6  
 48  UI22068  +* 60  85* 64 51 25 55 3  
 49  LNT2714 +  78† 40 55  49* 28 60 4  
   LNT2714 + 85 65 69 65 36 65 3  
 50  UI22743  +* 85 58 85* 65  32* 65 3  
 51  SV1038 +  85* 69   74*†  70* 36 75 4  
 52  LNT2747 +  40†  56* 64 44 30 63 6  
 53  UI23056 + 85* 56 66  50* 30 60 3  
 54  UI23152  +* 85 70  80* 45 46 60 5  
 55  UI23159  +* 85 85 73 62  36† 70 6  
 56  LNT2825  +* 85 85 85 70  45† 80 4  
 57  LNT2859 + 85  70* 85 42  30† 65 3  
 58  UI25281  +* 75 55 56 45 30 52 3  
 59  UI26021 + 85 82 78 75 42   71† 5  
Isolate  
number 
Isolate  
code 
Growth 
control Azithromycin Ceftriaxone Ciprofloxacin Doxycycline Gentamicin Penicillin G
Time to reach 
4+ growth 
(days) 
Additional 
observations 
 60  UI26702 + 85 85 85 65 42 85 3 Faint growth 
 61  UI27257 + 85 50 61 45 30 53 3  
   UI27257 + 85 84 75  60* 38 66 3  
 62  UI27365 + 85 64 57 59 35 65 5  
 63  UI27387 + 85 85  85* 65 39 67 3 Faint growth 
 64  LNT2987  +*  42† 62 60 46 33  75† 6  
 65  UI27739  +* 85 56 70 56 31 55 5  
 66  UI27845 +  85* 85 85 79 43 65 3 Faint growth 
 67  UI27877 + 85  70* 80 55 35 63 3  
 68  FS3849 +  85* 58 55 50 27 54 4  
  FS3849 +  70† 47    53*† 43 31  62* 9  
    FS3849 + 85 65 72 50 35 75 3  
 69  LNT3077 + 55 49 65 55 29 70 4  
 70  LNT3086  +*  85*  60†  53†  48† 30 61 4  
 71  LNT3102 +  75† 56  65† 35 31 54 6  
 72  UI30454 + 85 60 85 (4 days) 45  35* 60 5  
 73  LNT3110 + 85 75  60†  61* 38 77 4  
   LNT3110 + 85 75 Widespread Contamination 63 38   75† 3  
 74  UI30711 + 85 85 65 40  35† 65 6  
 75  UI30881 + 85 73 85 80  50* 85 3  
 76  UI32865 + 74  40* 56  44*  27* 57 6  
 77  UI33216  +*  85*  70*  (4 days) 63 40 
32  
(4 days) 68 5  
 78  SV547 + 85  57* 54†  47† 28 58 6  
 79  SV588 + 40  75†  (6 days) 55 37 32 56 6  
 80  UI36718 +  75* 50 55  40* 29 57 6  
Isolate  
number 
Isolate  
code 
Growth 
control Azithromycin Ceftriaxone Ciprofloxacin Doxycycline Gentamicin Penicillin G
Time to reach 
4+ growth 
(days) 
Additional 
observations 
 81  UI36788  +* 85 70 75  60† 36  (5 days)  65† 4  
 82  UI37443 +  85* 85 85 70 35 70 4  
 83  UI37640 + 85 75 75 70 40 70 6 Faint growth 
 Median 85 69 70 56 35 70 5  
 IQR  
 (1st to 3rd  
 quartiles) 
85 to 85 59 to 75 64 to 85 47 to 65 30 to 37 63 to 85 4 to 8 
 
  Mode 85 70 85 70 35 70 6  
  Minimum 37 40 40 34 25 52 3  
  Maximum 85 85 85 85 85 85 12  
 
 
 Range 48 45 45 51 60 33 9  
IQR = interquartile range; LVW = Leptospira Vanaporn Wuthiekanun; n/a = not available. 
 
 
